RxDoctor Payments Data

Michael O Brien

Family · Beaver, PANPI 1295082725

Payments from drug & device makers

$3,502in general payments, 2019–2025

Across 159 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Acadia Pharmaceuticals Inc$605
  • Neurocrine Biosciences, Inc.$555
  • Otsuka America Pharmaceutical, Inc.$361
  • Lilly USA, LLC$102
  • Mylan Specialty L.p.$83
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$3,502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,502 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,541
Medicare patients
162
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$67,276
XifaxanRifaximin27$40,471
EliquisApixaban95$32,341
OzempicSemaglutide28$28,850
RexultiBrexpiprazole29$22,961
JardianceEmpagliflozin57$17,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,588
FarxigaDapagliflozin Propanediol23$7,040
TradjentaLinagliptin22$6,071
KonvomepOmeprazole/Sodium Bicarbonate12$4,487
Aripiprazole22$3,810
Glucagon Emergency KitGlucagon14$3,774
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,839
Arnuity ElliptaFluticasone Furoate12$2,744
Permethrin34$2,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$555$67,27618 claims
Otsuka America Pharmaceutical, Inc.Rexulti$361$22,96129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Beaver

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →